674 related articles for article (PubMed ID: 26865800)
21. Topical dexamethasone γ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema.
Ohira A; Hara K; Jóhannesson G; Tanito M; Ásgrímsdóttir GM; Lund SH; Loftsson T; Stefánsson E
Acta Ophthalmol; 2015 Nov; 93(7):610-5. PubMed ID: 26201996
[TBL] [Abstract][Full Text] [Related]
22. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract.
Akinci A; Muftuoglu O; Altınsoy A; Ozkılıc E
Retina; 2011 Apr; 31(4):755-8. PubMed ID: 21124251
[TBL] [Abstract][Full Text] [Related]
23. Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema.
Ozdek S; Bahçeci UA; Gürelik G; Hasanreisoğlu B
J Diabetes Complications; 2006; 20(4):246-51. PubMed ID: 16798476
[TBL] [Abstract][Full Text] [Related]
24. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema.
Bakri SJ; Kaiser PK
Am J Ophthalmol; 2005 Feb; 139(2):290-4. PubMed ID: 15733990
[TBL] [Abstract][Full Text] [Related]
25. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).
Paccola L; Costa RA; Folgosa MS; Barbosa JC; Scott IU; Jorge R
Br J Ophthalmol; 2008 Jan; 92(1):76-80. PubMed ID: 17965109
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema.
Wang YS; Li X; Wang HY; Zhang ZF; Li MH; Su XN
Chin Med J (Engl); 2011 Feb; 124(3):352-8. PubMed ID: 21362332
[TBL] [Abstract][Full Text] [Related]
27. The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy.
Bakri SJ; Larson TA
Semin Ophthalmol; 2015 Jul; 30(4):276-80. PubMed ID: 24251435
[TBL] [Abstract][Full Text] [Related]
28. Effect of intravitreal triamcinolone acetonide or bevacizumab on choroidal thickness in eyes with diabetic macular edema.
Sonoda S; Sakamoto T; Yamashita T; Otsuka H; Shirasawa M; Kakiuchi N; Uchino E; Terasaki H; Kawano H
Invest Ophthalmol Vis Sci; 2014 Jun; 55(6):3979-85. PubMed ID: 24906857
[TBL] [Abstract][Full Text] [Related]
29. Quantitative evaluation of hard exudates in diabetic macular edema after short-term intravitreal triamcinolone, dexamethasone implant or bevacizumab injections.
Shin YU; Hong EH; Lim HW; Kang MH; Seong M; Cho H
BMC Ophthalmol; 2017 Oct; 17(1):182. PubMed ID: 28974211
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema.
Song JH; Lee JJ; Lee SJ
Korean J Ophthalmol; 2011 Jun; 25(3):156-60. PubMed ID: 21655039
[TBL] [Abstract][Full Text] [Related]
31. Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema.
Batioğlu F; Ozmert E; Parmak N; Celik S
Int Ophthalmol; 2007 Oct; 27(5):299-306. PubMed ID: 17453151
[TBL] [Abstract][Full Text] [Related]
32. Response of Retinal Sensitivity to Intravitreal Anti-angiogenic Bevacizumab and Triamcinolone Acetonide for Patients with Diabetic Macular Edema over One Year.
Mylonas G; Schranz M; Scholda C; Karst S; Reiter G; Baumann L; Schmidt-Erfurth U; Kriechbaum K
Curr Eye Res; 2020 Sep; 45(9):1107-1113. PubMed ID: 31961224
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal versus subtenon triamcinolone acetonide injection for diabetic macular edema: a systematic review and meta-analysis.
Qi HP; Bi S; Wei SQ; Cui H; Zhao JB
Curr Eye Res; 2012 Dec; 37(12):1136-47. PubMed ID: 22793880
[TBL] [Abstract][Full Text] [Related]
34. Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema.
Jonas JB; Spandau UH; Kamppeter BA; Vossmerbaeumer U; Harder B; Sauder G
Ophthalmology; 2006 May; 113(5):800-4. PubMed ID: 16530840
[TBL] [Abstract][Full Text] [Related]
35. Effect of intravitreal triamcinolone in diabetic macular edema unresponsive to intravitreal bevacizumab.
Jeon S; Lee WK
Retina; 2014 Aug; 34(8):1606-11. PubMed ID: 24553409
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema.
Faghihi H; Roohipoor R; Mohammadi SF; Hojat-Jalali K; Mirshahi A; Lashay A; Piri N; Faghihi Sh
Eur J Ophthalmol; 2008; 18(6):941-8. PubMed ID: 18988166
[TBL] [Abstract][Full Text] [Related]
37. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.
Liu Q; Hu Y; Yu H; Yuan L; Hu J; Atik A; Guan M; Li D; Li X; Tang S
Retina; 2015 Feb; 35(2):272-9. PubMed ID: 25105313
[TBL] [Abstract][Full Text] [Related]
38. Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery - preliminary 6 month results.
Lim LL; Morrison JL; Constantinou M; Rogers S; Sandhu SS; Wickremasinghe SS; Kawasaki R; Al-Qureshi S
Clin Exp Ophthalmol; 2016 May; 44(4):233-42. PubMed ID: 26871700
[TBL] [Abstract][Full Text] [Related]
39. The effects of intravitreal triamcinolone acetonide in diabetic macular edema refractory to anti-VEGF treatment.
Hong IH; Choi W; Han JR
Jpn J Ophthalmol; 2020 Mar; 64(2):196-202. PubMed ID: 31900869
[TBL] [Abstract][Full Text] [Related]
40. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema.
Soheilian M; Garfami KH; Ramezani A; Yaseri M; Peyman GA
Retina; 2012 Feb; 32(2):314-21. PubMed ID: 22234244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
